WHO Invites Expressions of Interest for mpox Vaccines, Bavarian Nordic Ready with Doses, Gavi Commits $500 Million
Expression of Interest Issued by WHO
The World Health Organization (WHO) has invited manufacturers of mpox vaccines to submit an Expression of Interest (EoI) for Emergency Use Listing (EUL).
EUL is a WHO procedure to assess the suitability of new or unlicensed vaccines for use during public health emergencies.
Bavarian Nordic Submits Data for EU Approval
Danish biotech company Bavarian Nordic announced on Friday that it had submitted data to the European Medicines Agency (EMA) for an extension of its mpox vaccine's approval.
The company has 30 million doses of its vaccine ready for immediate shipment.
Gavi Commits $500 Million for mpox Response
The Global Alliance for Vaccines and Immunization (Gavi) has pledged up to $500 million to support the procurement and distribution of mpox vaccines in affected countries.
This funding will be used to purchase and deliver vaccines to countries experiencing an escalating mpox outbreak.
WHO's Vaccine Prequalification Programme
The WHO's vaccines prequalification programme ensures the quality, safety, and efficacy of vaccines used in emergencies.
By prequalifying vaccines, the WHO provides assurance that candidate vaccines meet international standards.
Ongoing mpox Outbreak in Africa
The mpox outbreak in Africa has been escalating, with cases reported in multiple countries.
The WHO has declared the outbreak a public health emergency of international concern (PHEIC).
Symptoms of mpox
- Fever
- Headache
- Muscle aches
- Swollen lymph nodes
- Skin rash
Transmission of mpox
Mpox can be transmitted through close contact with an infected person, their bodily fluids, or contaminated surfaces.
The virus can enter the body through broken skin or mucous membranes.
Protection against mpox
Vaccination is the most effective way to protect against mpox.
The WHO recommends that people who are at risk of exposure to mpox get vaccinated.
Comments